Danaher stock touches 52-week low at $194.68 amid market shifts

Published 04/04/2025, 14:42
Danaher stock touches 52-week low at $194.68 amid market shifts

Danaher Corporation (NYSE:DHR) stock has reached a 52-week low, trading at $194.68, as investors navigate through a landscape of economic uncertainties and shifting market dynamics. The $138 billion market cap company, which InvestingPro data shows has maintained dividend payments for 33 consecutive years, currently trades at a P/E ratio of 37.2x. The science and technology company, known for its diversified portfolio of professional, medical, industrial, and commercial products and services, has experienced a notable decline over the past year. With revenue of $23.88 billion and an overall Financial Health Score of "GOOD" according to InvestingPro, the stock’s current position reflects a significant 1-year change, with Danaher’s shares falling by 22.21%. For deeper insights into DHR’s valuation and growth potential, including 12+ additional ProTips, check out the comprehensive Pro Research Report available on InvestingPro. This downturn mirrors broader market trends and investor sentiment, as the company looks to adapt and strengthen its market position in the face of ongoing challenges. Based on InvestingPro’s Fair Value analysis, the stock is currently trading near its Fair Value.

In other recent news, Danaher Corporation has declared an 18.5% increase in its regular quarterly cash dividend, raising it from $0.27 to $0.32 per share. This increase is scheduled for payment on April 25, 2025, to shareholders of record as of March 28, 2025. In another development, Stifel analysts upgraded Danaher’s stock rating from Hold to Buy, setting a new price target of $260, citing potential upsides in revenue and margins. Citi analysts also expressed a positive short-term view on Danaher, highlighting conservative guidance for the bioprocessing sector and cost-saving measures. Additionally, TD Cowen analysts maintained a Buy rating on Danaher, emphasizing the growth potential in the bioproduction sector. Danaher has also appointed Charles W. Lamanna to its Board of Directors and amended its 2007 Omnibus Incentive Plan, ensuring full vesting of stock options and units in the event of an employee’s death or disability. These recent developments reflect Danaher’s strategic initiatives and financial commitments aimed at enhancing shareholder value.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.